KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Alnylam Pharmaceuticals (ALNY) over the last 8 years, with Q3 2025 value amounting to $0.52.

  • Alnylam Pharmaceuticals' Debt to Equity changed N/A to $0.52 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.52, marking a year-over-year change of. This contributed to the annual value of $1.4 for FY2024, which is N/A changed from last year.
  • Per Alnylam Pharmaceuticals' latest filing, its Debt to Equity stood at $0.52 for Q3 2025.
  • Alnylam Pharmaceuticals' Debt to Equity's 5-year high stood at $1.4 during Q4 2024, with a 5-year trough of $0.48 in Q2 2025.
  • Its 3-year average for Debt to Equity is $0.91, with a median of $1.02 in 2025.
  • Over the last 5 years, Alnylam Pharmaceuticals' Debt to Equity had its largest YoY gain of 51032.2% in 2021, and its largest YoY loss of 51032.2% in 2021.
  • Alnylam Pharmaceuticals' Debt to Equity (Quarter) stood at $1.15 in 2021, then increased by 21.71% to $1.4 in 2024, then crashed by 62.91% to $0.52 in 2025.
  • Its Debt to Equity stands at $0.52 for Q3 2025, versus $0.48 for Q2 2025 and $1.02 for Q1 2025.